AstraZeneca PLC ADR closed 22.59% below its 52-week high of $87.68, which the company achieved on August 30th.

(Reuters) -AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical ...

AstraZeneca is a top healthcare company with a robust pipeline of drugs in development. Uber Technologies has been a growth beast in recent years, and robotaxis could open up a huge opportunity ...

In the latest market close, Astrazeneca (AZN) reached $64.90, with a -1.35% movement compared to the previous day. The stock's change was more than the S&P 500's daily loss of 1.57%. Elsewhere ...

Credit: aslysun / Shutterstock. AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase III trial. The trial evaluated the ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £110.00. The company’s shares opened today at p10,500. ...

It’s not HBO, it’s Max — but the new standalone logo for Warner Bros. Discovery‘s streamer now certainly looks like HBO’s at a glance. The Max streaming service has quietly launched a ...

Well, scientists have already proven it can be done. And now they’ve developed a new kind of transparent wood that acts like glass but with surprising advantages. Not only is it strong and ...

The PHERGain study was supported by F Hoffmann-La Roche. JMP-G reports consulting roles for Daiichi Sankyo, AstraZeneca, Roche, Gilead, Merck Sharp & Dohme, Eisai, Seattle Genetics, and Lilly; travel ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Merck KGaA, Pfizer and Sanofi were among more than 40 international business leaders who met with Xi in ...

The biotech linked BNT327 to a median overall survival (OS) of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and ...

Previous articleStockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.?